Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Trip Taylor - Investor Relations Kevin Danahy - President & Chief Executive Officer Darrin Uecker - Chief Technology Officer Mike Koffler - Vice President of Finance Robert Duggan – Executive Chairman Conference Call Participants Robert Lovgren – Medical Hope Productions Operator Good afternoon, ladies and gentlemen and thank you for standing by. Welcome to the Pulse Biosciences First Quarter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 46-5696597 (Sta ...

For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 46-5696597 (State or ...

Financial Data and Key Metrics Changes - Non-GAAP net loss for Q4 2022 was $8.1 million, an improvement from $11.5 million in Q4 2021 [24] - Cash, cash equivalents, and investments totaled $61.1 million as of December 31, 2022, compared to $28.6 million a year earlier and $69.2 million as of September 30, 2022 [25] - Cash used in Q4 2022 was $8 million, reduced from $13.4 million in the same period last year and $10.6 million in Q3 2022 [25] Business Line Data and Key Metrics Changes - The company has shifted focus to the treatment of atrial fibrillation (AF), a high-growth market valued at $8 billion, which is seen as a path for long-term value creation [9][10] - The development of two main devices, a cardiac clamp and a catheter, is underway, both utilizing the proprietary nsPFA technology [19][47] Market Data and Key Metrics Changes - The AF intervention market is projected to grow by more than 10% annually due to factors such as an aging population and increased clinical evidence [37] - Over 1.2 million catheter-based surgical ablations are performed annually, indicating a significant market opportunity [37] Company Strategy and Development Direction - The company aims to advance its nsPFA technology for AF treatment by developing a cardiac clamp and completing regulatory milestones for a catheter [38] - The strategy includes meeting with the FDA to discuss regulatory requirements for the cardiac clamp and preparing for human clinical use [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the technology's potential to disrupt the current treatment landscape for AF, emphasizing the safety and efficacy of nsPFA compared to thermal modalities [34][43] - The company is focused on long-term success and building a foundation for a viable business, with a clear understanding of the time and expertise required for execution [38] Other Important Information - The company has a strong patent portfolio with over 100 patents granted and another 100 filed, ensuring a competitive edge in the market [84] - The company plans to increase awareness of its technology through presentations at key industry events, such as the Heart Rhythm Society Meeting [22] Q&A Session Summary Question: Why pivot to cardiac? - Management indicated that the pivot was driven by physician feedback and promising preclinical outcomes, highlighting the significant market opportunity in cardiac applications [29][30] Question: How should success be viewed for Pulse Biosciences in 2023? - Success will be measured by advancing the cardiac clamp through the FDA regulatory path and completing catheter product milestones [31] Question: What was the significance of the AF Symposium poster? - The acceptance of the poster at the AF Symposium validated the technology and demonstrated interest from leading electrophysiologists [61]

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor – Investor Relations, Gilmartin Group Kevin Danahy – President and Chief Executive Officer Darrin Uecker – Chief Technology Officer Sandy Gardiner – Executive Vice President and Chief Financial Officer Conference Call Participants Operator Greetings and welcome to Pulse Biosciences Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-on ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bio ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Darrin Uecker - President and Chief Executive Officer Kevin Danahy - Chief Commercial Officer Sandra Gardiner - Executive Vice President and Chief Financial Officer Conference Call Participants Jeremy Pearlman - Maxim Group LLC Swayampakula Ramakanth - H.C. Wainwright & Co, LLC Operator Greetings, and welcome to Pulse Biosciences Second Qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bioscien ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Officer Sandra Gardiner - Chief Financial Officer Kevin Danahy - Chief Commercial Officer Conference Call Participants Christopher Cooley - Stephens Swayampakula Ramakanth - H.C. Wainwright Jeremy Pearlman - Maxim Group Operator Greetings, and welcome to Pulse Biosciences First Quarter 2022 Earnings Conference Call. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bioscie ...